Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing R...

Your unfiltered news center. ®

The world you see depends upon the news you get. ®

HOME

ARTS

RSS

Today's Date: April 1, 2023

HONDA DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Honda • Realty Income Publishes Third Annual Sustainability Report • New Birth Missionary Baptist Church Announces Outreach Activities, Plans for Easter Weekend • BEST-EVER FIRST QUARTER AND MARCH SALES FOR KIA AMERICA • REGiMMUNE Limited Licenses the Rights to Develop and Commercialize RGI-2001 To San Fu Biotech in Major Asian Countries • REDWIRE INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and D • UNice Hair Launches "UNice Empowering Workshop" Event • BLOCK DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Block • REATA PHARMACEUTICALS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the • Statement by Minister Hussen for Sikh Heritage Month • UNITE HERE Local 11 Rallies with LA Councilmember Curren Price to Endorse Boycott of Tommie and Thompson Hotels • Bass Named Women In Trucking Association's 2023 Driver of the Year • Statement by the Ministers of Crown-Indigenous Relations, Indigenous Services, and Northern Affairs on the Catholic Church's re • 160 Driving Academy Celebrates Women's History Month • RYVYL DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against RYVYL • TGT INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Target Corp. Investors with Substantial Losses Have Opp • Why We Need to Ban ChatGPT in Elementary Schools • TUP NOTICE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Tupperware Brands Corporation Investors to Secure Counsel Before Importa • INVIVYD DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Inv • Wild Rivers Waterpark Drops Dates For Camp Wild Rivers Junior Lifeguards, a One-of-a-Kind Weekly Summer Camp for Orange County,

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON , February 02 /Businesswire/ - Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema and focused on life-changing therapies for rare and niche allergic and immunological diseases, granted stock options to purchase 1,800 shares of Astria’s common stock on February 1, 2023 under Astria’s 2022 Inducement Stock Incentive Plan. The 2022 Inducement Stock Incentive Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of Astria.

The options were granted as an inducement material to an employee or employees entering into employment with Astria in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $13.36, which is equal to the closing price of Astria’s common stock on February 1, 2023 (the “Grant Date”), and will vest over a four-year period, with 25% of shares vesting on the first anniversary of the employee’s employment start date (which preceded the Grant Date) and the remaining shares vesting monthly on a ratable basis over the following 36 months, subject to the employee’s continued employment with Astria on such vesting dates. The options are subject to the terms and conditions of the 2022 Inducement Stock Incentive Plan and the terms and conditions of an award agreement covering the grant.

About Astria Therapeutics:

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema. Learn more about our company on our website, www.astriatx.com, or follow us on Twitter and Instagram @AstriaTx and on Facebook and LinkedIn.